Page last updated: 2024-09-04

atrasentan and sc 58125

atrasentan has been researched along with sc 58125 in 1 studies

Compound Research Comparison

Studies (atrasentan)	Trials (atrasentan)	Recent Studies (post-2010) (atrasentan)	Studies (sc 58125)	Trials (sc 58125)	Recent Studies (post-2010) (sc 58125)
358	41	108	93	0	15

Protein Interaction Comparison

Protein	Taxonomy	atrasentan (IC50)	sc 58125 (IC50)
Prostaglandin G/H synthase 2	Homo sapiens (human)		0.2316
Prostaglandin G/H synthase 2	Mus musculus (house mouse)		0.07

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F	1

Other Studies

1 other study(ies) available for atrasentan and sc 58125

Article	Year
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-15, Volume: 10, Issue:14 Topics: Animals; Atrasentan; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Endothelin A Receptor Antagonists; Endothelin-1; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Isoenzymes; Luciferases; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Nitrobenzenes; Ovarian Neoplasms; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrrolidines; Receptor, Endothelin A; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2004

Article

Year

Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-15, Volume: 10, Issue:14

Topics: Animals; Atrasentan; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Endothelin A Receptor Antagonists; Endothelin-1; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Isoenzymes; Luciferases; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Nitrobenzenes; Ovarian Neoplasms; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrrolidines; Receptor, Endothelin A; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2004